Recurrent Verrucous Carcinoma of the Oral Cavity Completed Phase 1 Trials for Bevacizumab (DB00112)

IndicationStatusPhase
DBCOND0029507 (Recurrent Verrucous Carcinoma of the Oral Cavity)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00023959Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck CancerTreatment